Search clinical trials for: gemtuzumab ozogamicin (GO)

Total 996 results

Versailles Hospital

Unknown

Retrospective Analysis of the Outcome of Patients With Relapsed/Refractory Acute Myeloid Leukemia Included in a Patient Named Program of Gemtuzumab Ozogamicin/Mylotarg® (MYLOR)

Leukemia, Myeloid, Acute

France
John Quigley
Pfizer; AbbVie

Active, not recruiting

Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113

Acute Myeloid Leukemia

United States
Brown University
Pfizer; The Miriam Hospital; Rhode Island Hospital

Active, not recruiting

Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
Versailles Hospital

Completed

Gemtuzumab Ozogamicin+Cytarabine vs Idarubicin+Cytarabine in Elderly Patients With AML.Mylofrance 4 (ALFA1401)

Acute Myeloid Leukemia

France
Nantes University Hospital
Chugai Pharmaceutical; French Innovative Leukemia Organisation

Completed

Efficacy of Gemtuzumab Ozogamycin for Patients Presenting an Acute Myeloid Leukemia (AML) With Intermediate Risk (LAM2006IR)

Acute Myeloid Leukemia

France
University Hospital Heidelberg

Terminated

Gemtuzumab Ozogamicin in Induction and Glasdegib in Postremission Therapy in Patients With AML (Acute Myeloid Leukemia) (GnG)

Acute Myeloid Leukemia

Germany
University Hospital Carl Gustav Carus

Unknown

Gemtuzumab Ozogamicin Before Allogeneic Stem Cell Transplantation

Acute Myeloid Leukemia | Allogeneic Transplantation

Germany
University of Aarhus

Completed

NOPHO-AML 2004 Study for Children With Acute Myeloid Leukemia

Acute Myeloid Leukemia

Denmark
Pfizer

Completed

CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse

Leukemia

United States
Pfizer

Completed

A Study Of Treatment Patterns And Clinical Outcomes In Patients Diagnosed With Acute Myeloid Leukemia Who Received Mylotarg in the Real-World

Leukemia, Myeloid, Acute

United States
Pfizer

Completed

CMA-676 in Treating Patients With Acute Myeloid Leukemia in First Relapse

Leukemia

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Gemtuzumab in Treating Patients With Myelodysplastic Syndrome

Myelodysplastic Syndromes

United States
European Organisation for Research and Treatment...
Gruppo Italiano Malattie EMatologiche dell'Adulto

Unknown

Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia (AML-19)

Leukemia

Belgium, Italy, Netherlands
Medical College of Wisconsin

Completed

Pracinostat and Gemtuzumab Ozogamicin (PraGO) in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Relapsed Adult AML

United States
Pfizer

Completed

Evaluating QTc, PK, Safety of Gemtuzumab Ozogamicin (GO) in Patients With CD33+ R/R AML

Pharmacokinetics | Safety | ECG

Canada, Spain, United States, Hungary, Poland, United Kingdom
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant

Acute Myelogenous Leukemia

United States
Merck Sharp & Dohme LLC

Terminated

SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia (P04717AM2)(TERMINATED)

Leukemia, Myeloid, Acute | Lymphoblastic Leukemia, Acute
Kanisa Pharmaceuticals

Completed

A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia

Leukemia, Myeloid
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia
Acute Leukemia French Association

Completed

DNR and AraC Combined to Fractionated Mylotarg® in Patients With First Relapse of AML (MYLOFRANCE2)

Acute Myeloid Leukemia

France
Genta Incorporated

Completed

Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia

Leukemia

United States
University Hospital Heidelberg
National Center for Tumor Diseases, Heidelberg

Completed

TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib (TEAM)

Acute Myeloid Leukemia

Germany
Weill Medical College of Cornell University
Pfizer; Jazz Pharmaceuticals

Terminated

CPX-351+GO in Subjects 55 Years Old, or Older, With AML (CPX GO)

Acute Myeloid Leukemia

United States
Shaare Zedek Medical Center

Recruiting

Vyxeos for Induction of Low- or Intermediate-risk.

Leukemia, Myeloid, Acute

Israel
University of Ulm

Completed

Study of Chemotherapy in Combination With All-trans Retinoic Acid (ATRA) With or Without Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia (AML) and Mutant Nucleophosmin-1 (NPM1) Gene Mutation

Acute Myeloid Leukemia

Germany, Austria
New York Medical College

Completed

SCT Plus Immune Therapy in Average Risk AML/MDS

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
The Cleveland Clinic
National Cancer Institute (NCI); University of Michigan

Completed

Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia

United States
Vor Biopharma

Recruiting

Allogeneic Engineered Hematopoietic Stem Cell Transplant (HCT) Lacking the CD33 Protein, and Post-HCT Treatment With Mylotarg, for Patients With CD33+ AML or MDS

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

United States, Canada
German Cancer Research Center
University Hospital Heidelberg; University Hospital Dresden

Not yet recruiting

Genetic Ablation of CD33 in HSC to Broaden the Therapeutic Index of CD33-directed Immunotherapy in Patients With AML (GALAXY33)

Relapsed/Refractory Acute Myeloid Leukemia (AML)

Germany
New York Medical College

Completed

Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Gemtuzumab Chemotherapy MRD Levels; Glasdegib Post-transplant, Adult Untreated, de Novo, Fav Interm Risk AML

Acute Myeloid Leukemia

Italy
UNC Lineberger Comprehensive Cancer Center
National Cancer Institute (NCI); Genzyme, a Sanofi Company

Terminated

Clofarabine and Gemtuzumab in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Leukemia

United States
M.D. Anderson Cancer Center

Completed

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Pfizer

No longer available

Expanded Access /Compassionate Use Protocol For Relapsed Or Refractory CD33 Positive AML Patients In The USA Without Access To Comparable Or Alternative Therapy (AML)

CD33 Positive Acute Myelogenous Leukemia

United States
University of Maryland, Baltimore
Hematologics, Inc

Recruiting

CLAG-GO for Patients With Persistent, Relapsed or Refractory AML

Acute Myeloid Leukemia Recurrent | Acute Myeloid Leukemia, Adult | Acute Myeloid Leukemia, Relapsed, Adult

United States
M.D. Anderson Cancer Center
Kura Oncology, Inc.

Not yet recruiting

A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia

Acute Myeloid Leukemia

United States
M.D. Anderson Cancer Center
Eisai Inc.

Completed

Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)

Myelodysplastic Syndrome | Acute Myelogenous Leukemia

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Comparison of Two Treatments in Intermediate and High-risk Acute Promyelocytic Leukemia (APL) Patients to Assess Efficacy in 1st Hematological Complete Remission and Molecular Remission

Leukemia, Myelocytic, Acute
Sidney Kimmel Comprehensive Cancer Center at Johns...
StemlineTherapeutics, Inc.

Recruiting

Tagraxofusp-erzs, an IL-3 Diphtheria Fusion Protein, in Combination With Gemtuzumab Ozogamicin in Patients With Relapsed/Refractory AML (GO-TAG)

Acute Myeloid Leukemia

United States
University of California, San Diego
Pfizer; Celgene Corporation

Completed

Combination 5-azacitidine and Gemtuzumab Ozogamicin Therapy for Treatment of Relapsed Acute Myeloid Leukemia (AML)

Acute Myeloid Leukemia

United States
University of North Carolina, Chapel Hill
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Recruiting

Evaluation of Child Care Staff Weight Management Program

Obesity

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Withdrawn

Gemtuzumab Ozogamicin in Treating Patients With Acute Myeloid Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditions
University of Minnesota

Completed

Go/No-Go Intervention for Weight Loss

Overweight and Obesity

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia

Acute Myeloid Leukemia
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0117 Gemtuzumab Ozogamicin Plus Cytarabine in Treating Patients With Relapsed Acute Myeloid Leukemia

Leukemia

United States
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Approved for marketing

Gemtuzumab Ozogamicin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Acute Promyelocytic Leukemia

Recurrent Adult Acute Myeloid Leukemia | Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Adult Acute Myeloid Leukemia With Del(5q) | Adult Acute Myeloid Leukemia With Inv(16)(p13;q22) | Adult Acute Myeloid Leukemia With t(16;16)(p13;q22) | Adult Acute Myeloid Leukemia With t(8... and other conditions

United States
Santa Clara Valley Health & Hospital System

Completed

Bowel Preparation for Inpatient Colonoscopy

Colon Cancer | Gastrointestinal Hemorrhage | Diverticulosis

United States
Weill Medical College of Cornell University

Completed

Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS

Acute Myeloid Leukemia | Myelodysplastic Syndrome

United States
Northwestern University

Completed

Set Your Goal: Engaging Go/No-Go Active Learning

Depression | Anxiety

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Gemtuzumab Ozogamicin and High-Dose Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Leukemia

United States, Puerto Rico

Search clinical trials for: gemtuzumab ozogamicin (GO)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Senegal

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations